Skip to main content
    E

    Ekso Bionics Holdings Inc (EKSO)

    Official site

    MEDICAL INSTRUMENTS & SUPPLIES

    $11.80
    +0.01 (+0.08%)

    Last updated: May 04, 2026 at 5:00 PM ET

    Ekso Bionics Holdings Inc (EKSO) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in US dollars.

    Ekso Bionics Holdings reported revenue of $12.80M for the fiscal year ended Dec 31, 2025, down 28.6% from the year before. That year, net income was -$11.70M with a net margin of -91.4%, operating cash flow was -$11.80M and free cash flow was -$11.99M. The quarter ended Mar 31, 2026 had revenue of $2.14M and net income of -$6.88M.

    Revenue and Margins

    The net margin was -91.4% in the fiscal year ended Dec 2025, the lowest of the 5 years shown with a net margin. Over the 9 years to Dec 2025, revenue fell from $14.22M, a compound annual decline of 1.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$12.80M-28.6%53.5%-104.1%-91.4%
    Dec 2024$17.93M-1.9%53.1%-58.4%-63.2%
    Dec 2023$18.28M+41.6%49.7%-82.7%-83.1%
    Dec 2022$12.91M+14.8%48.1%-120.5%-116.8%
    Dec 2021$11.25M+26.6%60.0%-123.0%-86.8%
    Dec 2020$8.88M-36.2%57.1%-144.8%-178.2%
    Dec 2019$13.92M+22.8%48.6%-119.6%-87.2%
    Dec 2018$11.33M+54.1%38.0%-238.5%-238.2%
    Dec 2017$7.35M-48.3%28.1%-429.9%-396.1%
    Dec 2016$14.22MN/A20.7%-194.0%-165.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$12.80M$17.93M$18.28M$12.91M$11.25M$8.88M$13.92M$11.33M$7.35M$14.22M
    Cost of revenue$5.95M$8.41M$9.20M$6.70M$4.50M$3.81M$7.15M$7.02M$5.28M$11.27M
    Gross profit$6.84M$9.51M$9.08M$6.21M$6.75M$5.07M$6.76M$4.31M$2.07M$2.95M
    Research and development$3.03M$3.87M$5.03M$3.63M$2.75M$2.47M$4.60M$5.85M$9.48M$8.88M
    Operating income-$13.33M-$10.46M-$15.11M-$15.56M-$13.83M-$12.86M-$16.64M-$27.03M-$31.61M-$27.59M
    Net income-$11.70M-$11.33M-$15.20M-$15.08M-$9.76M-$15.82M-$12.13M-$26.99M-$29.12M-$23.47M
    EBITDA-$9.81M-$9.45M-$13.20M-$14.04M-$9.09MN/A-$11.06M-$24.89M-$26.74M-$21.60M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$2.14M$3.14M$4.23M$2.06M$3.38M$5.09M$4.13M$4.95M$3.76M$4.85M$4.61M$4.70M
    Gross profit$1.07M$1.67M$2.55M$819.00K$1.81M$2.71M$2.21M$2.64M$1.95M$2.37M$2.46M$2.25M
    Operating income-$5.62M-$4.51M-$1.40M-$3.98M-$3.44M-$2.23M-$2.64M-$2.33M-$3.26M-$3.45M-$2.93M-$4.28M
    Net income-$6.88M-$4.67M-$1.42M-$2.71M-$2.89M-$3.41M-$2.07M-$2.42M-$3.43M-$3.21M-$3.37M-$4.23M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $2.49M exceeded cash and equivalents by $1.32M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$20.11M$26.65M$28.92M$40.90M$49.17M$20.60M$21.91M$17.66M$37.99M$24.43M
    Current assets$14.05M$18.84M$20.21M$31.04M$47.80M$18.42M$18.81M$14.97M$34.94M$20.68M
    Cash and equivalents$1.17M$6.49M$8.64M$20.52M$40.41M$12.86M$10.87M$7.66M$27.81M$16.85M
    Total liabilities$11.08M$13.95M$16.31M$15.46M$11.95M$16.16M$15.12M$14.93M$16.60M$17.89M
    Short-term debt$1.69M$1.68M$1.61M$2.65M$229.00K$548.00K$2.77M$2.37M$2.17M$108.00K
    Long-term debt$798.00K$3.85M$4.83M$3.77M$1.99M$9.11M$407.00K$2.65M$4.83M$6.79M
    Shareholder equity$9.03M$12.71M$12.61M$25.44M$37.22M$4.43M$6.80M$2.73M$21.39M$6.53M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$19.67M$20.11M$21.66M$23.17M$27.31M$26.65M$29.21M$26.98M$28.96M$28.92M$31.18M$33.99M
    Total liabilities$13.93M$11.08M$11.98M$12.24M$14.62M$13.95M$14.34M$14.93M$14.91M$16.31M$15.93M$16.18M
    Cash and equivalents$3.99M$1.17M$2.72M$5.24M$8.05M$6.49M$8.29M$5.88M$8.80M$8.64M$9.94M$13.31M
    Shareholder equity$2.09M$9.03M$9.68M$10.93M$12.69M$12.71M$14.87M$12.06M$14.05M$12.61M$15.26M$17.81M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$11.80M-$9.85M-$12.05M-$14.69M-$11.16M-$8.76M-$15.77M-$22.16M-$31.23M-$25.00M
    Capital expenditures$188.00K$37.00K$157.00K$194.00K$59.00K$59.00K$60.00K$131.00K$456.00K$1.10M
    Free cash flow-$11.99M-$9.88M-$12.21M-$14.88M-$11.21M-$8.81M-$15.83M-$22.30M-$31.68M-$26.09M
    Dividends paid$226.00KN/AN/AN/AN/AN/AN/AN/AN/A$10.35M
    Investing cash flow-$188.00K-$37.00K-$157.00K-$5.17M-$59.00K-$59.00K-$60.00K-$131.00K-$456.00K-$1.10M
    Financing cash flow$6.63M$7.77M$348.00K$176.00K$38.71M$10.70M$19.04M$2.27M$42.57M$23.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$2.12M-$4.33M-$2.06M-$3.44M-$1.97M-$1.43M-$2.28M-$2.67M-$3.47M-$1.58M-$3.35M-$2.90M
    Capital expenditures$0$50.00K$50.00K$40.00K$10.00K$21.00K$8.00K$0$8.00K$43.00K$17.00K$55.00K
    Free cash flow-$2.12M-$4.38M-$2.11M-$3.48M-$1.98M-$1.45M-$2.29M-$2.67M-$3.47M-$1.63M-$3.37M-$2.96M
    Last 12 quarters

    Frequently Asked Questions About EKSO

    What is Ekso Bionics Holdings' annual revenue?

    Ekso Bionics Holdings reported revenue of $12.80M for the fiscal year ended Dec 31, 2025.

    How fast is Ekso Bionics Holdings' revenue growing?

    Revenue was down 28.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.

    Is Ekso Bionics Holdings profitable?

    No. Ekso Bionics Holdings reported net income of -$11.70M for the fiscal year ended Dec 31, 2025, with a net margin of -91.4%.

    How much free cash flow does EKSO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$11.80M minus capital expenditures of $188.00K produced free cash flow of -$11.99M.

    How much debt does Ekso Bionics Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $798.00K, short-term debt of $1.69M and cash and equivalents of $1.17M.